Using Tirzepatide to treat obesity in young adults with Prader-Willi Syndrome and hypothalamic obesity
The Effects of Tirzepatide in Young Adults With Prader-Willi Syndrome, Hypothalamic Obesity and General Non-Syndromic Obesity
This study is testing if a weight loss medication called Tirzepatide can help young adults with Prader-Willi Syndrome and hypothalamic obesity lose weight and improve their health.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 36 (estimated) |
| Ages | 18 Years to 26 Years |
| Sex | All |
| Sponsor | Seattle Children's Hospital Academic / other |
| Locations | 3 sites (Saint Paul, Minnesota and 2 other locations) |
| Trial ID | NCT06901245 on ClinicalTrials.gov |
What this trial studies
This research compares the effectiveness of Tirzepatide, a weight loss medication, in young adults aged 18-26 with Prader-Willi Syndrome, hypothalamic obesity, and general obesity. Participants will receive weekly doses of the medication for approximately 56-60 weeks, during which they will undergo various health assessments, including medical record reviews, physical exams, and laboratory tests. The study aims to evaluate how Tirzepatide affects weight and other health factors in these populations compared to those with obesity unrelated to genetic syndromes.
Who should consider this trial
Good fit: Ideal candidates are young adults aged 18-26 with a BMI in the obesity range and a diagnosis of Prader-Willi Syndrome, hypothalamic obesity, or general obesity.
Not a fit: Patients who do not have obesity or related conditions, or those who are unable to participate in the required study procedures, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new treatment option for weight management in individuals with Prader-Willi Syndrome and hypothalamic obesity.
How similar studies have performed: Other studies have shown promising results with GLP-1 agonists like Tirzepatide in obesity management, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Individuals 18-26 years with a BMI in the obesity range (BMI ≥95th percentile for age and sex or ≥30 kg/m2) with either 1) genetically confirmed diagnosis of PWS, 2) hypothalamic obesity as defined by damage to the medial hypothalamic region resulting in dysregulation of satiety and energy balance as diagnosed by a physician, 3) general obesity unrelated to a genetic syndrome or underlying medical condition * In a stable care setting at least 6 months prior to enrollment * Able and willing to participate in study visits including tolerating blood draws, urine samples and tolerate DXA scan. * Ability to take weekly subcutaneous tirzepatide * Consistent caregiver if they are not independent * Stable diet and exercise regimen for at least 6 months prior to enrollment * Able to use contraceptive methods if able to conceive offspring in order to prevent unintentional pregnancy during the study Exclusion Criteria: * Current or recent (within 3 months of start of study drug initiation) use of weight loss medications * Current use of insulin or sulfonylurea or other medication affecting insulin secretion or GLP1 clearance * Current or prior use of any GLP1A or DPP4 inhibitor during the 6 months before screening * Any medications that may affect the study endpoints * Significant weight change (\>3% weight gain or loss) in the last 2 months prior to enrollment * Change in dose of chronic endocrine medications (testosterone, estrogen, levothyroxine, or growth hormone medications) \>10%/kg/day for at least 3 months prior to study * Current pregnancy or desire to become pregnant within study period, current lactation * History of recurrent pancreatitis, CKD, gastroparesis * Chronic/acute heart, kidney, or liver disease * Personal or family history of medullary thyroid carcinoma or MEN syndrome type 2 * Uncontrolled diabetes (A1C \>8.5%) * DVT * Cancer within the previous 5 years * Current participation in an interventional clinical study * Previous or planned surgical treatment for obesity * Individuals with current substance abuse equivalnt to moderate or severe based on DSM 5 criteria (Hasin DS, 2013) * Any suicidal ideation in the past year * Unable to perform any of the procedures for the study * Have a body weight, height, and/or width that that prohibits the ability to obtain accurate measurements according to the DXA manufacturer's specification * Any condition that would prevent successful participation in the study.
Where this trial is running
Saint Paul, Minnesota and 2 other locations
- Children's Minnesota — Saint Paul, Minnesota, United States (Recruiting)
- Vanderbilt University Medical Center — Nashville, Tennessee, United States (Recruiting)
- Seattle Children's Hospital — Seattle, Washington, United States (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.